Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035

Lilly's Mounjaro and Zepbound Earn USD 16.1 Billion in One Quarter, Novo's Obesity Sales Rise 22% and Oral GLP-1 Pills Open a New Front: Precedence Research Company Intelligence on Leaders, Pipelines, Investments and Deals

Ottawa, Nov. 16, 2026 (GLOBE NEWSWIRE) --

The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and is projected to reach USD 64.96 billion by 2035 at a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate, while Pfizer , Roche , Amgen and a group of emerging developers are investing to win share in the Next wave of therapies.

Precedence Research today released updated company intelligence on the global anti-obesity drugs market, focusing on the companies that lead it and the investments, pipelines and deals that will decide its future. The market is valued at USD 8.96 billion in 2026 and is forecast to reach USD 64.96 billion by 2035.

Two companies set the pace. Eli Lilly's third-quarter 2026 revenue rose 39% to USD 24.4 billion, with Mounjaro at USD 10.7 billion and Zepbound at USD 5.4 billion, and its oral GLP-1 Foundayo, approved on April 1, 2026, has started to add sales. Novo Nordisk 's obesity sales rose 22% at constant exchange rates to DKK 26.1 billion, helped by the Wegovy pill launched in the U.S. in January 2026. Both companies raised their 2026 outlooks.

Challengers are investing heavily to catch up. Pfizer completed its acquisition of Metsera for up to USD 10 billion, Roche signed a USD 5.3 billion collaboration with Zealand Pharma , and Amgen has started Phase 3 trials of MariTide. Meanwhile, the leaders are building new pipelines and plants: Lilly's retatrutide delivered up to 22.6% weight loss in Phase 3, Novo has filed CagriSema with the FDA, and Lilly is investing USD 50 billion in U.S. manufacturing. This release profiles the top companies and what their moves mean for competition through 2035.

Full report: https://www.precedenceresearch.com/anti-obesity-drugs-market

Request a sample: https://www.precedenceresearch.com/sample/4896

Market at a Glance

Market Indicator Value
Market size, 2025 → 2026 USD 7.14 billion → USD 8.96 billion
Market size, 2035 USD 64.96 billion
CAGR, 2026–2035 24.71%
U.S. market, 2025 → 2035 USD 3.59 billion → around USD 33.17 billion (24.90% CAGR)
Largest region / fastest-growing region North America (more than 67%) / Asia Pacific
Largest type / leading channel Prescription drugs (92%) / retail & online pharmacy

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Figure 1: Anti-Obesity Drugs Market Snapshot

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Prescription GLP-1 and dual-agonist therapies make up almost all revenue, and North America accounts for more than two-thirds of it. Asia Pacific is the fastest-growing region as Lilly, Novo Nordisk and regional developers such as Innovent, LG Chem and Zydus expand there.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Top Companies in the Anti-Obesity Drugs Market

Figure 2: Top Anti-Obesity Drug Companies, Latest Results (Q3 2026)

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Company Key Products / Assets Latest Reported Data Position
Eli Lilly Zepbound, Mounjaro (tirzepatide), Foundayo (orforglipron), retatrutide Q3 2026 revenue USD 24.4B (+39%); Mounjaro USD 10.7B (+65%); Zepbound USD 5.4B (+49%); Foundayo USD 184M Market leader; 2026 revenue guidance raised to USD 91–92B
Novo Nordisk Wegovy injection, Wegovy pill, CagriSema Q3 2026 obesity sales DKK 26.1B (+22% CER); Wegovy pill DKK 5.4B; Wegovy injection DKK 20.4B (-2% CER) No. 2; pill launched in 8 markets; outlook raised Nov 4, 2026
Pfizer Metsera pipeline Acquisition completed Nov 2025 (up to USD 10B) Re-entering obesity with long-acting injectables
Roche Zealand Pharma collaboration USD 5.3B deal (May 2025) Building an Amylin -based franchise
Amgen MariTide Phase 3 program launched, including a 1,200-patient switch study (May 2026) Targets less frequent dosing
Astrazeneca / Boehringer Ingelheim Clinical-stage candidates Named key players in the report Next -generation mechanisms
Rhythm Pharmaceuticals Setmelanotide Rare genetic obesity Niche specialist
Innovent / LG Chem / Zydus Regional candidates Named key players in the report Asia Pacific challengers

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Lilly and Novo Nordisk hold a lead that other companies will struggle to close before the end of the decade. Lilly is growing faster, with tirzepatide sales rising in every region AND Int. Mounjaro revenue up 93% in the third quarter. Novo Nordisk is shifting its growth to the Wegovy pill, which recorded about 3.6 million prescriptions in the quarter and more than 8 million since launch, while injectable Wegovy sales were slightly lower.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Company Pipelines: The Next Generation of Obesity Drugs

Company Candidate Mechanism / Format Latest Milestone
Eli Lilly Retatrutide Triple agonist (GIP, GLP-1, glucagon), weekly injection Phase 3 TRIUMPH-3: 21.6–22.6% weight loss at 80 weeks; FDA filing planned Q1 2027
Eli Lilly Foundayo (orforglipron) Oral small-molecule GLP-1, no food or water restrictions FDA approved April 1, 2026; Q3 sales USD 184M
Novo Nordisk CagriSema GLP-1 plus Amylin , weekly injection Filed with FDA Dec 2025; 22.7% weight loss in REDEFINE 1
Novo Nordisk Wegovy pill Oral semaglutide U.S. launch Jan 5, 2026; DKK 10.9B in 9M 2026 sales
Amgen MariTide Long-acting GLP-1 antibody-peptide Phase 3 trials started (2026)
Pfizer Metsera assets Long-acting injectables Acquired Nov 2025
Roche / Zealand Petrelintide program Amylin analogue USD 5.3B collaboration (May 2025)

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

The pipeline shows where competition is heading: higher weight loss (retatrutide and CagriSema at more than 20%), pills that are easier to take and to manufacture, and longer dosing intervals. Companies that combine strong efficacy with convenient formats and manufacturing scale will capture the most share.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Company Investments and Deals

Figure 3: Company Investments and Deals in Obesity

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

  • Lilly is building scale. Lilly has committed USD 50 billion to U.S. manufacturing across ten sites announced since 2020. In September 2026 it broke ground on a USD 6.5 billion Houston plant that will make Foundayo and other medicines.
  • Pfizer bought its way back in. Pfizer completed the acquisition of Metsera for up to USD 10 billion in November 2025, after ending its own oral GLP-1 program.
  • Roche partnered for Amylin . Roche 's USD 5.3 billion collaboration with Zealand Pharma gives it an Amylin -based candidate to combine with its own programs.
  • Novo is investing to defend share. Novo Nordisk expects about DKK 50 billion in capital expenditure in 2026 and has launched the Wegovy pill in eight markets.

These investments show that manufacturing capacity and access to new mechanisms are now the main competitive levers. Building peptide and oral manufacturing capacity takes years, which protects the leaders but also creates opportunities for contract manufacturers and device suppliers.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Key Company Developments

Figure 4: Top Company Moves in Anti-Obesity Drugs, 2025–2026

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Pills are changing the market. Novo's Wegovy pill launched in the U.S. on January 5, 2026, at self-pay prices of USD 149–299 a month and is available at more than 70,000 pharmacies. Lilly's Foundayo was approved on April 1, 2026, as the first daily GLP-1 pill without food or water restrictions.

What it indicates: Oral drugs widen access in primary care and emerging markets, and the competition between the two leaders is moving from injections to pills.

Prices are falling as volumes rise. Pricing agreements announced in November 2025 opened Medicare coverage for eligible patients and set prices around USD 245 a month for government programs.

What it indicates: Revenue growth will come from more patients rather than higher prices, rewarding the companies with the largest supply.

Late-stage data are raising the bar. Lilly reported in July 2026 that retatrutide produced up to 22.6% weight loss at 80 weeks in TRIUMPH-3, and Novo's CagriSema showed 22.7% weight loss in REDEFINE 1.

What it indicates: New entrants will need to match more than 20% weight loss or offer clear advantages in dosing, tolerability or cost.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Key Market Drivers

  • Rising obesity prevalence and related heart, kidney and metabolic disease.
  • Strong clinical results from GLP-1, dual and triple agonists.
  • Oral formulations and lower prices that widen access.
  • Medicare coverage, employer programs and ePharmacy and telehealth channels.
  • Large manufacturing investments that ease supply limits.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Major Challenges

  • High long-term costs for payers and employers.
  • Side effects, discontinuation and weight regain after stopping therapy.
  • Peptide, pen and fill-finish capacity limits.
  • Compounded and counterfeit products.
  • Strong dominance of two leaders, which raises the bar for new entrants.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Emerging Opportunities

  • Oral GLP-1 therapies for primary care and emerging markets.
  • Triple agonists and Amylin combinations for greater weight loss.
  • Longer-acting injectables with monthly or less frequent dosing.
  • Asia Pacific, the fastest-growing region.
  • Contract manufacturing and devices for peptides, pens and oral products.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Company Ecosystem

Figure 5: Anti-Obesity Drugs Company Ecosystem, 2026

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

The supply side combines the two market leaders, large pharmaceutical challengers, emerging developers such as Viking Therapeutics, Structure Therapeutics and Terns, and a manufacturing base that includes Novo Holdings' Catalent, Thermo Fisher, Lonza and device makers. The demand side includes pharmacies and telehealth platforms, payers and PBMs, employers and care providers.

Customer and Buyer Intelligence

Target Account Group Decision-Makers Purchase Signals Commercial Opportunity
Pharma business development Head of BD, Metabolic R&D Head Pipeline gaps, competitor data In-licensing and acquisitions
Employers CHRO, Benefits Director Rising GLP-1 claims Managed coverage programs
Health plans and PBMs Chief Pharmacy Officer Price agreements, oral launches Formulary and utilization contracts
Pharmacies and telehealth Category and Operations Heads Self-pay demand for pills Direct-to-consumer fulfillment
CDMOs and device makers BD and Operations Heads Plant announcements Peptide, oral and pen supply

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

How Precedence Research Supports Decision-Making

Master Dataset provides company, segment and regional data for obesity drugs and adjacent markets such as the anti-obesity medication, pharmaceutical and pharmacy markets. It helps teams size each company's position by product and region.

Precedence Quadrant ranks obesity drug companies on sales, pipeline strength, manufacturing scale and access, helping business development teams and investors screen leaders and challengers.

Interactive Intelligence Dashboard tracks company results, approvals, trial readouts, price changes and deals, so teams can respond to competitor moves quickly.

Quality & Manufacturing Intelligence maps company and CDMO capacity for peptides, oral products and devices, supporting supply and partnering decisions.

Customized Research answers specific questions, such as competitor benchmarking, pill versus injection uptake or partner screening in Asia Pacific.

Solution What It Provides How It Helps
Master Dataset Company, segment and region data on obesity drugs Sizes each company's position
Precedence Quadrant Ranking of leaders and challengers Screens partners and acquisition targets
Interactive Dashboard Live tracking of results, approvals and deals Times competitive responses
Quality & Manufacturing Intelligence Company and CDMO capacity mapping Supports supply and partnering
Customized Research Benchmarking and uptake studies Answers decision-specific questions

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Why Continuously Updated Intelligence Matters

The competitive picture in obesity changes every quarter. Monthly updates suit teams tracking prescriptions, prices and launches. Quarterly updates match Lilly and Novo Nordisk earnings. Six-monthly updates follow trial readouts and FDA decisions such as CagriSema and retatrutide, and annual updates support investors reviewing company share and market size. Precedence Research offers all four update cycles.

Strategic Outlook

  • CEOs and CXOs: Lilly and Novo Nordisk will lead through the late 2020s; challengers must differentiate on dosing, tolerability or price.
  • Strategy and business development teams: deals such as Pfizer –Metsera and Roche –Zealand set valuations for late-stage obesity assets.
  • R&D leaders: more than 20% weight loss is becoming the efficacy benchmark; orals and long-acting formats are key.
  • Procurement and supply teams: secure peptide, pen and oral manufacturing capacity early.
  • Investors: emerging developers with differentiated mechanisms remain prime acquisition targets.
  • Manufacturers and suppliers: Lilly's USD 50 billion U.S. build-out and Novo's capital spending drive demand for equipment and contract services.

Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher

Call to Action

To compare the top anti-obesity drug companies and track their Next moves, explore the full report or speak with a Precedence Research analyst.

Fill out the form for relevant samples, case studies, and examples. sales@precedenceresearch.com

Related Reports

  1. Anti-Obesity Medication Market: https://www.precedenceresearch.com/anti-obesity-medication-market
  2. Over the Counter Drugs Market: https://www.precedenceresearch.com/over-the-counter-drugs-market
  3. U.S. Over the Counter Drugs Market: https://www.precedenceresearch.com/us-over-the-counter-drugs-market
  4. Pharmaceutical Market: https://www.precedenceresearch.com/pharmaceutical-market
  5. Biopharmaceutical Market: https://www.precedenceresearch.com/biopharmaceutical-market
  6. Biotechnology Market: https://www.precedenceresearch.com/biotechnology-market
  7. Pharmacy Market: https://www.precedenceresearch.com/pharmacy-market
  8. ePharmacy Market: https://www.precedenceresearch.com/epharmacy-market
  9. Pharmacy Automation Market: https://www.precedenceresearch.com/pharmacy-automation-market
  10. Pharmacy Benefit Management Market: https://www.precedenceresearch.com/pharmacy-benefit-management-market
  11. U.S. Pharmacy Benefit Management Market: https://www.precedenceresearch.com/us-pharmacy-benefit-management-market
  12. Health Insurance Market: https://www.precedenceresearch.com/health-insurance-market
  13. Healthcare Payer Services Market: https://www.precedenceresearch.com/healthcare-payer-services-market
  14. Digital Health Market: https://www.precedenceresearch.com/digital-health-market
  15. Population Health Management Market: https://www.precedenceresearch.com/population-health-management-market
  16. Healthcare Analytics Market: https://www.precedenceresearch.com/healthcare-analytics-market
  17. Precision Medicine Market: https://www.precedenceresearch.com/precision-medicine-market
  18. Clinical Trials Market: https://www.precedenceresearch.com/clinical-trials-market
  19. Monoclonal Antibodies Market: https://www.precedenceresearch.com/monoclonal-antibodies-market
  20. Artificial Intelligence Market: https://www.precedenceresearch.com/artificial-intelligence-market

About Precedence Research

Precedence Research is a global market intelligence and consulting company. It provides market sizing and forecasts, competitive and company analysis, customer and buyer intelligence and customized research across healthcare, pharmaceuticals, consumer health, ICT , energy, chemicals and materials and other industries, helping executives and investors make evidence-based decisions.

Our Partners

Connect Group With Us

  • USA: +1 804 441 9344
  • APAC: +61 485 981 310 or +91 87933 22019
  • Singapore: +65 3105 1271
  • Europe: +44 7383 092 044
  • Email: sales@precedenceresearch.com

Social Media